Literature DB >> 18440229

2-Trifluoroacetylthiophenes, a novel series of potent and selective class II histone deacetylase inhibitors.

Philip Jones1, Matthew J Bottomley, Andrea Carfí, Ottavia Cecchetti, Federica Ferrigno, Paola Lo Surdo, Jesus M Ontoria, Michael Rowley, Rita Scarpelli, Carsten Schultz-Fademrecht, Christian Steinkühler.   

Abstract

The identification of class II HDAC inhibitors has been hampered by lack of efficient enzyme assays, in the preceding paper two assays have been developed to improve the efficiency of these enzymes: mutating an active site histidine to tyrosine, or by the use of a trifluoroacetamide lysine substrate, allowing screening to identify class II HDAC inhibitors. Herein, 2-trifluoroacetylthiophenes have been demonstrated to inhibit class II HDACs, resulting in the development of a series of 5-(trifluoroacetyl)thiophene-2-carboxamides as novel, potent and selective class II HDAC inhibitors. X-ray crystal structures of the HDAC 4 catalytic domain with a bound inhibitor demonstrate these compounds are active site inhibitors and bind in their hydrated form.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18440229     DOI: 10.1016/j.bmcl.2008.02.026

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  15 in total

Review 1.  Selective class IIa HDAC inhibitors: myth or reality.

Authors:  Eros Di Giorgio; Enrico Gagliostro; Claudio Brancolini
Journal:  Cell Mol Life Sci       Date:  2014-09-05       Impact factor: 9.261

2.  The histone deacetylase inhibitor ITF2357 decreases surface CXCR4 and CCR5 expression on CD4(+) T-cells and monocytes and is superior to valproic acid for latent HIV-1 expression in vitro.

Authors:  Shay Matalon; Brent E Palmer; Marcel F Nold; Antonio Furlan; Afework Kassu; Gianluca Fossati; Paolo Mascagni; Charles A Dinarello
Journal:  J Acquir Immune Defic Syndr       Date:  2010-05-01       Impact factor: 3.731

3.  Pimelic diphenylamide 106 is a slow, tight-binding inhibitor of class I histone deacetylases.

Authors:  C James Chou; David Herman; Joel M Gottesfeld
Journal:  J Biol Chem       Date:  2008-10-24       Impact factor: 5.157

Review 4.  Histone deacetylase inhibitors: Potential in cancer therapy.

Authors:  P A Marks; W-S Xu
Journal:  J Cell Biochem       Date:  2009-07-01       Impact factor: 4.429

5.  Structural and functional analysis of the human HDAC4 catalytic domain reveals a regulatory structural zinc-binding domain.

Authors:  Matthew J Bottomley; Paola Lo Surdo; Paolo Di Giovine; Agostino Cirillo; Rita Scarpelli; Federica Ferrigno; Philip Jones; Petra Neddermann; Raffaele De Francesco; Christian Steinkühler; Paola Gallinari; Andrea Carfí
Journal:  J Biol Chem       Date:  2008-07-08       Impact factor: 5.157

Review 6.  Immunomodulatory effects of deacetylase inhibitors: therapeutic targeting of FOXP3+ regulatory T cells.

Authors:  Liqing Wang; Edwin F de Zoeten; Mark I Greene; Wayne W Hancock
Journal:  Nat Rev Drug Discov       Date:  2009-10-26       Impact factor: 84.694

Review 7.  Small molecule inhibitors of zinc-dependent histone deacetylases.

Authors:  Florence F Wagner; Michel Weїwer; Michael C Lewis; Edward B Holson
Journal:  Neurotherapeutics       Date:  2013-10       Impact factor: 7.620

Review 8.  Trials with 'epigenetic' drugs: an update.

Authors:  Angela Nebbioso; Vincenzo Carafa; Rosaria Benedetti; Lucia Altucci
Journal:  Mol Oncol       Date:  2012-10-06       Impact factor: 6.603

Review 9.  The many roles of histone deacetylases in development and physiology: implications for disease and therapy.

Authors:  Michael Haberland; Rusty L Montgomery; Eric N Olson
Journal:  Nat Rev Genet       Date:  2009-01       Impact factor: 53.242

10.  Assessment of the trifluoromethyl ketone functionality as an alternative zinc-binding group for selective HDAC6 inhibition.

Authors:  Yves Depetter; Silke Geurs; Flore Vanden Bussche; Rob De Vreese; Jorick Franceus; Tom Desmet; Olivier De Wever; Matthias D'hooghe
Journal:  Medchemcomm       Date:  2018-05-18       Impact factor: 3.597

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.